Jankovic J, Hunter C, Dolimbek B Z, Dolimbek G S, Adler C H, Brashear A, Comella C L, Gordon M, Riley D E, Sethi K, Singer C, Stacy M, Tarsy D, Atassi M Z
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA.
Neurology. 2006 Dec 26;67(12):2233-5. doi: 10.1212/01.wnl.0000249308.66959.43.
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
在这项针对100例颈部肌张力障碍患者的多中心研究中，我们使用一种新型小鼠保护试验检测了B型肉毒毒素（BTX-B）的免疫原性，并将临床反应与阻断抗体（Abs）的存在情况相关联。三分之一在基线时BTX-B抗体阴性的患者在最后一次随访时变为BTX-B抗体阳性。因此，BTX-B的高抗原性限制了其长期疗效。
